Novel chemotherapies in development for management of castration-resistant prostate cancer

Abstract

Epothilones could be efficacious as an additional therapy in patients who respond to docetaxel chemotherapy. A role for IMiDs, perhaps in combination with chemotherapy or androgen pathway inhibitors, remains to be elucidated.

Role of inflammasomes and their regulators in prostate cancer initiation, progression and metastasis

“…It has been estimated that one in every 36 men will die of prostate cancer, and that it is one of the most prevalent cancers among men [1]. Castration-resistant prostate cancer (CRPC) is the most clinically challenging form and accounts for many deaths [1,2]. The role of inflammation as an independent risk factor for prostate cancer development is rather a debatable issue.…”

Prostate Changes Related to Therapy: With Special Reference to Hormone Therapy

“…At present, several antiangiogenic drugs have been tested in clinical trials. One of these is thalidomide, which has been approved by the FDA to treat patients with multiple myeloma [57]. It was combined with chemotherapy in an early-phase study of men with advanced prostate cancer.…”

Co‐delivery of docetaxel and retinoic acid by poly (ethylene glycol)‐retinoic acid conjugates based micelles for synergistic prostate cancer therapy

“…DTX can also regulate cell signalling and expression of certain genes, inducing apoptosis [5,6]. DTX based chemotherapy has been the most used therapeutic option after castration-resistant prostate cancer develops [7][8][9][10]. Available studies show that treatment of prostate cancer cells with DTX induces phosphorylation of Bcl-2 and abrogates the normal anti-apoptotic function of Bcl-2, resulting in apoptosis [11,12].…”